Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Paul Scorer"'
Autor:
Magdalena Zajac, Marietta Scott, Marianne Ratcliffe, Paul Scorer, Craig Barker, Hytham Al-Masri, Marlon C. Rebelatto, Jill Walker
Publikováno v:
Diagnostic Pathology, Vol 14, Iss 1, Pp 1-10 (2019)
Abstract Background Antibodies targeting the programmed cell death-1 (PD-1)/PD-ligand 1 (PD-1/PD-L1) checkpoint have shown promising clinical activity in patients with advanced urothelial carcinoma (UC). Expression of PD-L1 in UC tumors has been inve
Externí odkaz:
https://doaj.org/article/4877dc5bab8d486eb643d9fe5d131069
Autor:
Paul Scorer, Marietta Scott, Nicola Lawson, Marianne J. Ratcliffe, Craig Barker, Marlon C. Rebelatto, Jill Walker
Publikováno v:
Diagnostic Pathology, Vol 13, Iss 1, Pp 1-10 (2018)
Abstract Background Several anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) therapies have shown encouraging safety and clinical activity in a variety of tumor types. A potential role for PD-L1 testing in identifyi
Externí odkaz:
https://doaj.org/article/43ffde86cf27475dba967a42ba02277c
Publikováno v:
PLoS ONE, Vol 14, Iss 4, p e0215393 (2019)
Four immunohistochemistry (IHC) diagnostic assays have been approved for tumour PD-L1 protein assessment in the clinic. However, mRNA detection by in situ hybridisation (ISH) could be utilised as an alternative to protein detection. Detecting spatial
Externí odkaz:
https://doaj.org/article/690fc558424848148459142673976f69
Autor:
Jill Walker, Marlon C. Rebelatto, Hytham Al-Masri, Paul Scorer, Marietta Scott, Craig Barker, Anita Midha, Alan Sharpe, Marianne J. Ratcliffe
Supplementary Table S1. Comparison of PD-L1 diagnostic assays for patients with NSCLC Supplementary Table S2. Detailed scoring criteria for each assay in the study Supplementary Table S3. Demographics of patients who provided study samples Supplement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07aacfa0b54063413c092e13aaeca054
https://doi.org/10.1158/1078-0432.22466039
https://doi.org/10.1158/1078-0432.22466039
Autor:
Jill Walker, Marlon C. Rebelatto, Hytham Al-Masri, Paul Scorer, Marietta Scott, Craig Barker, Anita Midha, Alan Sharpe, Marianne J. Ratcliffe
Purpose: Immunotherapies targeting programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) demonstrate encouraging antitumor activity and manageable tolerability in non–small cell lung cancer (NSCLC), especially in patients with h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac6ca4005b4ba30e410ab5f659432998
https://doi.org/10.1158/1078-0432.c.6526226
https://doi.org/10.1158/1078-0432.c.6526226
Autor:
Asimina Tsirka, Charo Garrido, Marietta Scott, Paul Scorer, Anne-Marie Boothman, Tsuyoshi Matsuo, Craig Barker
Publikováno v:
Cancer Research. 83:P6-04
Background & Objective Trastuzumab deruxtecan is effective in HER2-positive (IHC3+ or ISH-positive) and HER2-low (IHC1+; IHC2+/ISH-negative) breast cancer. We assessed consistency of HER2-positive and HER2-low categorization by IHC across and between
Autor:
Keith M. Kerr, Marco Loddo, Gareth Williams, Marietta Scott, Paul Cane, Craig Barker, David Snead, Andrew G. Nicholson, Sylvie Lantuejoul, Erik Thunnissen, Paul Scorer
Publikováno v:
Williams, G H, Nicholson, A G, Snead, D R J, Thunnissen, E, Lantuejoul, S, Cane, P, Kerr, K M, Loddo, M, Scott, M L J, Scorer, P W & Barker, C 2020, ' Interobserver Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in NSCLC ', Journal of Thoracic Oncology, vol. 15, no. 4, pp. 550-555 . https://doi.org/10.1016/j.jtho.2019.11.010
Journal of Thoracic Oncology, 15(4), 550-555. International Association for the Study of Lung Cancer
Journal of Thoracic Oncology, 15(4), 550-555. International Association for the Study of Lung Cancer
Introduction: The VENTANA PD-L1 (SP263) Assay is approved for use with anti–programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) therapies in NSCLC and urothelial carcinoma. Here, we investigate interobserver reliability of the SP263
Publikováno v:
Journal of Clinical Oncology. 39:1021-1021
1021 Background: Breast cancer patients with HER2 low expression by immunohistochemistry (IHC), defined as IHC1+ or IHC2+ without gene amplification (ISH-) do not respond to conventional anti-HER2 therapies such as trastuzumab or pertuzumab. The HER2
Autor:
Marianne Schimpl, Nicola Lawson, Carly I. Dix, Edmond Wong, Craig Barker, Liam Hutchinson, Eileen McCall, Jill Walker, Paul Scorer, Christopher D. Stubbs, Emma DeVries, James K. Hunt, Gareth H. Williams
Publikováno v:
Modern Pathology
Programmed cell death ligand-1 (PD-L1) expression levels in patient tumor samples have proven clinical utility across various cancer types. Several independently developed PD-L1 immunohistochemical (IHC) predictive assays are commercially available.
Publikováno v:
PLoS ONE, Vol 14, Iss 4, p e0215393 (2019)
Four immunohistochemistry (IHC) diagnostic assays have been approved for tumour PD-L1 protein assessment in the clinic. However, mRNA detection by in situ hybridisation (ISH) could be utilised as an alternative to protein detection. Detecting spatial